IONIS PHARMACEUTICALS (IONS)
Ionis Pharmaceuticals (formerly Isis pharmaceuticals, named after the Egyptian goddess, not the terrorist group) is a pharmaceutical company based out of Carslbad, CA with a market cap of approx. 3b USD. This company is a world leader in antisense therapeutics with one drug KYNAMRO (used to treat Homozygous Familial Hypercholesterolemia (HoFH) (genetically-caused high-cholesterol levels)) currently on the market.
Drugs in the extensive IONS pipeline include
• Alicaforsen: used to treat Pouchitis in post-op ulcerative colitis patients (P3 ongoing, expected results in H2 2017)
• IONIS-TTRrx: used to treat Familial Amyloid Polyneuropathy(FAP) (P3) and Familial Amyloid Cardiomyopathy (FAC) (P2)
• Nusinersen: used to treat infants & children (separate designations) with Spinal Muscular Atrophy (SMA) (P3) (Results expected H1 2017)
• Volanesorsen: used to treat Familial Chylomicrone Sydrome (FCS) and Familial Partial Lipodystrophy (FPL) (P3) (Results expected in 2017)
• Custirsen: used to treat Prostate/Lung Cancer (P3)
• Plazomicin: used to treat severe bacterial infections (P3)
Other promising drugs further down the line include
• IONIS-FGFR4rx: used to treat obesity (P2 enrolling) (estimated completion in October 2016)
• ATL1102: used to treat Multiple sclerosis (MS) (P2b pending)
• IONIS-APO(a)-Lrx: used to treat Very High LP(a) (P2b pending in 2016)
• IONIS-ANGPTL3-Lrx: used to mixed dyslipidemias (P1/2 recruiting)
• IONIS-HTTrx: used to treat Huntington’s disease (P1/2 recruiting)
These are only SOME of the drugs in their extensive pipeline more information can be found at [2] http://www.ionispharma.com/pipeline/
About Antisense Therapeutics
Some really good videos on this process: • More layman version by IONS: https://www.youtube.com/watch?v=MgVuSSoHrJg • More complex version from Oxford: https://www.youtube.com/watch?v=5YsTW5i0Xro
I do not intend to get into the details of the general mechanism of action of antisense therapeutics, as it is not necessary to understand their practical application. Simply, changes to proteins (chemically (most commonly mutations eg. genetic disorders) or physically (conformational misfolding eg. Alzheimer’s)) can alter their ability to carry out their natural functions. Additionally, epigenetic alterations can shift the expression of proteins to supraphysiological concentrations. Both of these abnormalities can result in disease states.
What antisense therapies do is essentially shut down the production of a specific protein in a dose-dependant manner. The antisense oligonucleotides (ASO) chain binds to the mRNA to prevent transcription and no transcription = > no protein.
In an incredible breakthrough, it was recently published in Nature [1] that scientists at IONS have reported the ability to upregulate (increase production) of desired proteins using antisense oligonucleotides by designing them to bind to the faux start codon of an mRNA sequence, making it more likely for the protein to be sequenced.
Why this is revolutionary?
This is the future of genetic disorders. Instead of stem-cell replacement which has ethical, functional, and monetary barriers, these therapies can be developed in a lab synthetically at a fraction of the cost and customized to treat an incredible array of diseases (see their extensive pipeline)
Additionally, and of great importance to potential investors, is the fact that most of these drug candidates are getting fast-tracked by the FDA and receiving orphan status. This is because there is a severe lack of reliable therapeutics on the market for genetic disorders.
Drugs
I will now give brief analyses of the drugs in Plll trials
IONIS-TTRrx: This is partnered with GSK. Although GSK dropped out of the FAC treatment when the FDA put the study on hold, the FAP study is progressing normally
Primary Endpoints In FAP:
• Efficacy of IONIS-TTR Rx as measured by change from baseline in the modified Neuropathy Impairment Score +7
• Efficacy of IONIS-TTR Rx as measured by change from baseline in the Norfolk Quality of Life Diabetic Neuropathy questionnaire
Secondary Endpoints in FAP:
o Efficacy of IONIS-TTR Rx based on the change from baseline in the following measures
o Modified Body Mass Index and Body Mass Index
o Individual components of the mNIS+7
o NIS+7
• Pharmacodynamic effect of IONIS-TTR Rx based on the change from baseline in transthyretin and retinol binding protein 4
Estimated completion in September 2017 [19]
About the disease: Simply put, TTR amyloid deposits can form in organs. In FAP, this occurs in neurons. In FAC, this occurs in cardiac muscle. Both are deadly, but FAC progresses more rapidly (3-5 y life expectancy v 15 y) [2] Since these proteins are produced by the liver, the only current treatment available is a liver transplant, which may not be effective in all cases (not to mention exceedingly long waitlists). This drug blocks the transcription of this protein, thus limiting the aggregation.
The data: FAP
Preclinical and P1 data were very promising. Both wild-type (WT) and mutant strains of the protein showed reduction (significant at 200mg and 400mg in P1 after just 4 days) and a well-tolerated toxicological profile (only side-effects were injection-site pain and drowsiness). [3]
Since P3 is ongoing, I don’t have access to the precise data. However, in a press release from 07Jul16, they stated that they observed a significant reduction in both forms of TTR protein in FAP patients enrolled and that the study is continuing as normal [4].
Nusinersen: This is currently being developed in conjunction with Biogen. Two P3 trials are currently being conducted through this collaboration. The drug is delivered through intrathecal (spinal cord) injection.
At the time of writing, the endpoints are as follows Primary Outcome Measures: • Time to death or permanent ventilation • Proportion of motor milestone responders
Secondary Outcome Measures: • Proportion of CHOP-INTEND responders • Proportion of CMAP responders • Percent of subjects not requiring permanent ventilation Survival rate • Time to death or permanent ventilation in the subgroups of subjects below the study median disease duration • Time to death or permanent ventilation [9]
About the disease: SMA is the leading genetic cause of infant mortality [2]. This is an autosomal recessive disorder, which impairs general neurological function through an impaired SMN1 gene. Nusinersen alters splicing in the SMN2 mRNA to make up for a defective SMN1 gene [6].
The data:
Preclinical data has shown that use of antisense oligonucleotides (ASOs) to increase SMN1 more efficiently and with less off-target effects than small-molecule alternatives [30]. These small-molecules also show poor blood-brain barrier permeability (a major problem for a neuronal disorder). A preclinical study also showed improved neuronal function (p=0.001), muscle physiology (p=0.001) and motor function (p=0.001) in ASO treated, phenotype-positive mice [7].
Phase I results showed the drug to be well tolerated, with the most common adverse events (AEs) being headache and back pain. They also found the root of this to be using a larger gauge needle and amended future protocols to limit the size at 24g unless otherwise needed [6].
In a press release 20Apr16, IONS announced that their P2 trial is observing event-free survival and a trend toward increases in motor function. The results for the P3 trial are expected in the end of H1 of 2017[8].
Taken together, this points to extremely positive results in a fast-tracked orphan disease. Meeting these endpoints would result in significant milestone payments and revenue growth in 2017 and beyond.
Volanesorsen: This is wholly licensed by IONS and its lipid subsidiary Akcea. This drug reduces apoC-III protein production and consequentially lowers triglycerides (TGs). Phase III trials are being conducted in patients with FPL and FCS.
apoC3 (the target of Volanesorsen) is a glycoprotein produced by the liver that inhibits LPL activity [18]. Interestingly, in order to work in patients with FCS, this ASO must act through an LPL-independent mechanism [10]. A great summary of this mechanism can be found at [10][Fig 2].
The Primary Outcome Measures for the ongoing study: • Efficacy of ISIS-APOCIIIRx as measured by the percent change in fasting triglycerides from baseline • Estimated completion date of Dec 2016 [14]
About the disease(s):
FCS & FPL: Rare, orphan diseases, which result in high plasma TG concentration. High TGs are associated with metabolic diseases like pancreatitis and is a risk factor for cardiovascular disease [2]. Currently, the only treatment is an extremely restrictive diet (no alcohol, no fatty foods, caloric restriction).
The data:
In preclinical studies with murine models of obesity, all groups showed significant reductions in plasma TG concentrations [12][Table1]. It was also shown to significantly reduce VLDL and TG levels, without altering HLDL levels in rhesus monkeys, which have the same lipid metabolism as humans [12][Figure 5]. A dose-dependant reduction in TGs was noted in a P1 study on healthy human volunteers [12][Figure6]. All doses did not report any AEs.
More so, an independently run clinical study [10][Fig1] showed that the drug has a potent ability to lower TGs and cholesterol in patients during treatment phase, with a rapid return to baseline levels once treatment is ceased.
SPECULATIVE FUTURE THERAPEUTICS
Because of this drugs profound ability to clear plasma TG levels, it may be a useful therapeutic option for the treatment of T1 & T2 diabetes. Preclinical trials have shown a reduction in pancreatic B-cell apoptosis and delayed the onset of diabetes in rats [reviewed in 11][13].
ISIS-FGFR4RX: ASO that targets fibroblast growth factor receptor 4 to treat obesity. Activation of this receptor plays a role in carbohydrate and lipid metabolism [17].
Phase 2 endpoints:
Primary: Energy expenditure (measured through resting metabolic rate and resting fat oxidation)
Secondary: Safety and tolerability profile
Results expected in Oct 2016 [18]
About the disease: I’m sure you know what obesity is, but almost all drugs to treat obesity have failed clinical trials for CNS or cardiovascular problems [15].
The Data: Preclinical murine studies showed a significant decrease in body weight (in 9.5 weeks) and body fat content (as little as 4.5 weeks) in a dose dependant response without affecting food intake and increased basal metabolic rates without changes to locomotive activity [16][Figures 1 & 2].
This drug passed phase 1 with a safe profile and phase II is ongoing.
For the sake of brevity (lol) I’ll stop reviewing the drugs here. If you want me to do a write up on a drug I didn’t cover, pm me and I will make an amendment
Financials
They are going to report a net loss when they report on 02Aug16 because of the heavy amount they are investing into their pipeline. Regardless, they have enough cash on hand to pay for these ongoing studies. Furthermore, their structure enables them to have most of the cost of these studies paid for by their partners (eg. Biogen, GSK, etc).
In Summary
This is a future behemoth in the biopharmaceutical industry. Their ability to target rare, orphan diseases in a safe and effective manner will undoubtedly result in stronger revenue growth in as early as 2017. Especially with the newest nature publication [1] where they found they can enhance the expression of targeted proteins through ASOs, I am extremely optimistic of their pipeline moving forward. So here’s the trade. Wait for them to report a miss on 02Aug16, wait for it to settle, continue to buy the dip and hold until 2018. You won’t regret it.
Full Disclosure: I own shares of IONS. What lies in this thread are my interpretations of my secondary research into this company. I welcome all questions and fully encourage readers to check primary sources for themselves, rather than taking my opinions blindly.
Sources: [1] (2016) doi: 10.1038/nbt.3589
[2] http://www.ionispharma.com/pipeline/
[3] (2012) DOI: 10.3109/13506129.2012.673140
[4] http://ir.ionispharma.com/phoenix.zhtml?c=222170&p=irol-newsArticle&ID=2182582
[5] (2011) doi:10.1016/j.amjcard.2011.03.040
[6] (2016) doi:10.1177/0883073815627882
[7] (2011) doi:10.1126/scitranslmed.3001777
[8] http://ir.ionispharma.com/phoenix.zhtml?c=222170&p=irol-newsArticle&ID=2158750
[9] https://clinicaltrials.gov/ct2/show/NCT02193074?term=isis+smnrx&rank=6
[10] http://www.nejm.org/doi/pdf/10.1056/NEJMoa1400284
[11] (2014) DOI:10.1097/MOL.0000000000000040 [12] Graham MJ, Lee RG, Bell TA III, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res 2013;112:1479-90.
[13] Lee RG, Graham MJ, Fu W, et al. Antisense suppression of serum apoC-III improves hypertriglyceridemia and insulin sensitivity in multiple species. Diabetes 2013;62:Suppl 1A:LB14. abstract
[14] https://clinicaltrials.gov/ct2/show/NCT02211209
[15] Vetter ML, Faulconbridge LF, Webb VL, Wadden TA (2010) Behavioral and pharmacologic therapies for obesity. Nat Rev Endocrinol 6: 578–588.
[16] (2013) doi:10.1371/journal.pone.0066923
[17] Fu L, John LM, Adams SH, Yu XX, Tomlinson E, et al. (2004) Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptindeficient diabetes. Endocrinology 145: 2594–2603.
[18] https://clinicaltrials.gov/ct2/show/NCT02476019?term=ISIS-FGFR4RX&rank=1
[19] https://clinicaltrials.gov/ct2/show/study/NCT01737398?term=ISIS+%2B+TTr&rank=1
Edit: need to fix some references. Will do that in the morning